Compare CXII & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CXII | MNPR |
|---|---|---|
| Founded | 2026 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 597.4M | 587.4M |
| IPO Year | 2026 | 2019 |
| Metric | CXII | MNPR |
|---|---|---|
| Price | $10.49 | $72.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $130.17 |
| AVG Volume (30 Days) | 27.3K | ★ 121.1K |
| Earning Date | N/A | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.05 | $50.07 |
| 52 Week High | $10.99 | $124.82 |
| Indicator | CXII | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 44.76 |
| Support Level | $10.34 | $66.88 |
| Resistance Level | $10.45 | $75.20 |
| Average True Range (ATR) | 0.03 | 4.84 |
| MACD | 0.02 | 1.02 |
| Stochastic Oscillator | 41.18 | 63.28 |
Churchill Capital Corp XII is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.